Approximately 25,000 allogeneic hematopoietic cell transplants are performed worldwide each year for a variety of malignant and non-malignant conditions. Graft-versus-host disease represents one of the most frequent complications and is a major source of long-term morbidity and mortality. Whereas acute graft-versus-host disease is induced by recognition of host tissues as foreign by immunocompetent donor cells, the pathogenesis of chronic graft-versus-host disease is not as well understood, and continues to be a major treatment challenge. Part I of this two-part series reviews the epidemiologic factors, classification, pathogenesis, and clinical manifestations of acute and chronic graft-versus-host disease. Part II discusses the topical, physical, and systemic treatment options available to patients with graft-versus-host disease.Le texte complet de cet article est disponible en PDF.
Key words : fasciitis, fibrosis, graft-versus-host disease, hematopoietic cell transplantation
Abbreviations used : ANA, APC, BAFF, GVHD, GVT, HCT, HPC, HLA, MiHC, NIH, Tregs
| Supported in part by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research.
| Reprints not available from the authors.